Rheumatologists' awareness of and screening practices for hepatitis B virus infection prior to initiating immunomodulatory therapy

Jonathan G. Stine, Omar S. Khokhar, John Charalambopoulos, Victoria K. Shanmugam, James H. Lewis

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Objective. To assess the degree of awareness of the American College of Rheumatology (ACR) guidelines and package insert information on the screening for and management of hepatitis B virus (HBV) infection by rheumatologists in patients receiving immunomodulation drug therapies. Method. A questionnaire survey was administered to a nationwide sample of 1,000 members of the ACR. Each participating physician answered questions regarding their awareness of the risk of HBV reactivation, familiarity with published guidelines regarding HBV reactivation, their decision process in screening patients for HBV, knowledge of antiviral treatments for HBV, personal experience with HBV reactivation, and preferred approach to prophylaxis and subsequent monitoring of those patients. Results. Responses were highly variable with regard to awareness, screening, and treatment options. The overall response rate was 15.3%. Of those surveyed, 7.4% had seen HBV reactivation. Depending on the agent, 19-53% were aware of manufacturers' warnings for HBV reactivation within drug package inserts. Nearly three-quarters (72%) would screen for HBV reactivation regardless of the presence/absence of manufacturers' warnings. Only 69% reported performing universal screening prior to initiating therapy with biologic disease-modifying antirheumatic drugs. The majority (81%) would defer to a gastroenterologist/ hepatologist to determine prophylactic therapy for HBV. Only 22% had managed patients who were given prophylaxis against HBV reactivation while receiving immunosuppressants. Conclusion. Based on this survey, improving education among rheumatologists regarding the risks of HBV reactivation and its prevention for patients receiving immunosuppressants seems warranted. More specific consensus guidelines are recommended to achieve universal screening as the standard of care in these patients, especially with the increasing prevalence of HBV infection estimated in the US.

Original languageEnglish (US)
Pages (from-to)704-711
Number of pages8
JournalArthritis Care and Research
Volume62
Issue number5
DOIs
StatePublished - May 1 2010

Fingerprint

Immunomodulation
Virus Diseases
Hepatitis B virus
Guidelines
Immunosuppressive Agents
Rheumatologists
Drug Labeling
Product Labeling
Biological Therapy
Antirheumatic Agents
Rheumatology
Physiologic Monitoring
Standard of Care
Antiviral Agents
Consensus
Therapeutics

All Science Journal Classification (ASJC) codes

  • Rheumatology

Cite this

Stine, Jonathan G. ; Khokhar, Omar S. ; Charalambopoulos, John ; Shanmugam, Victoria K. ; Lewis, James H. / Rheumatologists' awareness of and screening practices for hepatitis B virus infection prior to initiating immunomodulatory therapy. In: Arthritis Care and Research. 2010 ; Vol. 62, No. 5. pp. 704-711.
@article{9e599387ace84397a703f043379cb0b9,
title = "Rheumatologists' awareness of and screening practices for hepatitis B virus infection prior to initiating immunomodulatory therapy",
abstract = "Objective. To assess the degree of awareness of the American College of Rheumatology (ACR) guidelines and package insert information on the screening for and management of hepatitis B virus (HBV) infection by rheumatologists in patients receiving immunomodulation drug therapies. Method. A questionnaire survey was administered to a nationwide sample of 1,000 members of the ACR. Each participating physician answered questions regarding their awareness of the risk of HBV reactivation, familiarity with published guidelines regarding HBV reactivation, their decision process in screening patients for HBV, knowledge of antiviral treatments for HBV, personal experience with HBV reactivation, and preferred approach to prophylaxis and subsequent monitoring of those patients. Results. Responses were highly variable with regard to awareness, screening, and treatment options. The overall response rate was 15.3{\%}. Of those surveyed, 7.4{\%} had seen HBV reactivation. Depending on the agent, 19-53{\%} were aware of manufacturers' warnings for HBV reactivation within drug package inserts. Nearly three-quarters (72{\%}) would screen for HBV reactivation regardless of the presence/absence of manufacturers' warnings. Only 69{\%} reported performing universal screening prior to initiating therapy with biologic disease-modifying antirheumatic drugs. The majority (81{\%}) would defer to a gastroenterologist/ hepatologist to determine prophylactic therapy for HBV. Only 22{\%} had managed patients who were given prophylaxis against HBV reactivation while receiving immunosuppressants. Conclusion. Based on this survey, improving education among rheumatologists regarding the risks of HBV reactivation and its prevention for patients receiving immunosuppressants seems warranted. More specific consensus guidelines are recommended to achieve universal screening as the standard of care in these patients, especially with the increasing prevalence of HBV infection estimated in the US.",
author = "Stine, {Jonathan G.} and Khokhar, {Omar S.} and John Charalambopoulos and Shanmugam, {Victoria K.} and Lewis, {James H.}",
year = "2010",
month = "5",
day = "1",
doi = "10.1002/acr.20209",
language = "English (US)",
volume = "62",
pages = "704--711",
journal = "Arthritis Care and Research",
issn = "2151-464X",
publisher = "John Wiley and Sons Inc.",
number = "5",

}

Rheumatologists' awareness of and screening practices for hepatitis B virus infection prior to initiating immunomodulatory therapy. / Stine, Jonathan G.; Khokhar, Omar S.; Charalambopoulos, John; Shanmugam, Victoria K.; Lewis, James H.

In: Arthritis Care and Research, Vol. 62, No. 5, 01.05.2010, p. 704-711.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Rheumatologists' awareness of and screening practices for hepatitis B virus infection prior to initiating immunomodulatory therapy

AU - Stine, Jonathan G.

AU - Khokhar, Omar S.

AU - Charalambopoulos, John

AU - Shanmugam, Victoria K.

AU - Lewis, James H.

PY - 2010/5/1

Y1 - 2010/5/1

N2 - Objective. To assess the degree of awareness of the American College of Rheumatology (ACR) guidelines and package insert information on the screening for and management of hepatitis B virus (HBV) infection by rheumatologists in patients receiving immunomodulation drug therapies. Method. A questionnaire survey was administered to a nationwide sample of 1,000 members of the ACR. Each participating physician answered questions regarding their awareness of the risk of HBV reactivation, familiarity with published guidelines regarding HBV reactivation, their decision process in screening patients for HBV, knowledge of antiviral treatments for HBV, personal experience with HBV reactivation, and preferred approach to prophylaxis and subsequent monitoring of those patients. Results. Responses were highly variable with regard to awareness, screening, and treatment options. The overall response rate was 15.3%. Of those surveyed, 7.4% had seen HBV reactivation. Depending on the agent, 19-53% were aware of manufacturers' warnings for HBV reactivation within drug package inserts. Nearly three-quarters (72%) would screen for HBV reactivation regardless of the presence/absence of manufacturers' warnings. Only 69% reported performing universal screening prior to initiating therapy with biologic disease-modifying antirheumatic drugs. The majority (81%) would defer to a gastroenterologist/ hepatologist to determine prophylactic therapy for HBV. Only 22% had managed patients who were given prophylaxis against HBV reactivation while receiving immunosuppressants. Conclusion. Based on this survey, improving education among rheumatologists regarding the risks of HBV reactivation and its prevention for patients receiving immunosuppressants seems warranted. More specific consensus guidelines are recommended to achieve universal screening as the standard of care in these patients, especially with the increasing prevalence of HBV infection estimated in the US.

AB - Objective. To assess the degree of awareness of the American College of Rheumatology (ACR) guidelines and package insert information on the screening for and management of hepatitis B virus (HBV) infection by rheumatologists in patients receiving immunomodulation drug therapies. Method. A questionnaire survey was administered to a nationwide sample of 1,000 members of the ACR. Each participating physician answered questions regarding their awareness of the risk of HBV reactivation, familiarity with published guidelines regarding HBV reactivation, their decision process in screening patients for HBV, knowledge of antiviral treatments for HBV, personal experience with HBV reactivation, and preferred approach to prophylaxis and subsequent monitoring of those patients. Results. Responses were highly variable with regard to awareness, screening, and treatment options. The overall response rate was 15.3%. Of those surveyed, 7.4% had seen HBV reactivation. Depending on the agent, 19-53% were aware of manufacturers' warnings for HBV reactivation within drug package inserts. Nearly three-quarters (72%) would screen for HBV reactivation regardless of the presence/absence of manufacturers' warnings. Only 69% reported performing universal screening prior to initiating therapy with biologic disease-modifying antirheumatic drugs. The majority (81%) would defer to a gastroenterologist/ hepatologist to determine prophylactic therapy for HBV. Only 22% had managed patients who were given prophylaxis against HBV reactivation while receiving immunosuppressants. Conclusion. Based on this survey, improving education among rheumatologists regarding the risks of HBV reactivation and its prevention for patients receiving immunosuppressants seems warranted. More specific consensus guidelines are recommended to achieve universal screening as the standard of care in these patients, especially with the increasing prevalence of HBV infection estimated in the US.

UR - http://www.scopus.com/inward/record.url?scp=77951725797&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951725797&partnerID=8YFLogxK

U2 - 10.1002/acr.20209

DO - 10.1002/acr.20209

M3 - Article

C2 - 20461789

AN - SCOPUS:77951725797

VL - 62

SP - 704

EP - 711

JO - Arthritis Care and Research

JF - Arthritis Care and Research

SN - 2151-464X

IS - 5

ER -